Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Xenome Limited (Xenome) has reported that MedImmune, the biologics unit of AstraZeneca, has exercised its option to obtain exclusive licenses to four peptides from its xdiscover venom peptide library against an undisclosed target involved in a key pain pathway.
Subscribe to our email newsletter
The xdiscover library is a proprietary collection of more than 2000 primarily venom-derived peptides and is the result of a unique genomics capability that allows for the highly efficient discovery of novel peptides from cone snail venom tissue.
Xenome said that the decision to exercise this option follows a research license agreement announced in January 2009, under which MedImmune gained access to Xenome’s Xdiscover venom peptide library to exclusively screen for drug candidates against two undisclosed targets involved in key pain pathways.
The financial terms of the licenses remain confidential, however Xenome will be eligible to receive undisclosed milestone and royalty payments associated with the ongoing development of product candidates derived from the peptides.
Ian Nisbet, CEO of Xenome, said: “Xenome is pleased with the ongoing interest in its discovery platform. We look forward to realising the potential of this collaboration with MedImmune.”